YES, ENETS is finally on Twitter! 🙌

Congratulations to Aurel Perren and ilaria marinoni and team. Patient-derived tumoroids of high-grade NEC for therapy response prediction and vulnerabilities identification. A step forward toward precision medicine in #NEN . A joint effort Charité - Universitätsmedizin Berlin
👉 link.springer.com/article/10.103…

NETTER-2 reports significantly improved PFS in Ki67 10-55% GEP-NETS with first-line #Lutathera vs ⬆️ dose SSA, HR 0.27. Similar benefit in subgroups. #GI24 ⁦LACNETS⁩ ⁦CarcinoidCancer CCF⁩ ⁦Thor Halfdanarson⁩

What is the carcinoid syndrome😳? Many mediators have been postulated, but what is truly the evidence? See our new review Endocrine Society Journals academic.oup.com/edrv/advance-a… Erasmus MC DBNETS Neuroendocrine Cancer

🦓At the meeting of the Advisory Board of the ENETS, the European #NeuroendocrineTumor Society🦓
@ Frascati, Rome, Italy🇮🇹
Working with friends to help advance the Society, its members, NET research&treatment and most of all:
🦓NET patients!
Hans Hofland Stefano Partelli Aurel Perren

Testing with hypertonic-saline stimulation was superior to testing with arginine stimulation in the diagnosis of arginine vasopressin deficiency. Read the full results: nej.md/49yN7VD

Editorial: Testing for Arginine Vasopressin Deficiency nej.md/3FVPe8u

Our suggested approach to the enigmatic insulinoma out now in jcem. A great Basel-Rotterdam collaboration🇳🇱🇨🇭 .

And there's the next #ENETS guidance paper🤩: non-functioning Pan-NET. onlinelibrary.wiley.com/doi/10.1111/jn… Splendid effort and congrats to all involved Justo P. Castaño 🔬🧬🧫#SinCienciaNoHayFuturo Louis de Mestier Stefano Partelli Aurel Perren Enrique Grande

#ESMO23
LBA53 - Alliance A021602: Cabozantinib vs placebo for advanced NET after progression on prior therapy (CABINET)

mPFS
Extra-panNET➡️8.2 vs 3.2 mo (HR:0.41)
panNET➡️13.7 vs 3.0 mo (HR:0.25)

New option in previously treated progressive NET?

OncoAlert

Really enjoyed the first Dutch Belgian NET Society conference. Truely a constructive, collaborative and relaxing atmosphere. Thanks to the amazing board and all participants DBNETS annemiek walenkamp Timon Vandamme Koen Dreijerink NETNECkanker Willem Lybaert Christophe Deroose Jules Derks, MD, PhD Anne-Marie Dingemans

Trial Alert!

ACTION-1 is now open at all three Mayo Clinic sites.

Phase III trial of alpha particle PRRT w/ Ac-225 DOTATATE vs. provider's choice of SOC therapy for pts w/ progressive G1/G2 GEPNETs and prior Lu-177 PRRT.

Very simplified schema below

clinicaltrials.gov/study/NCT05477…

ACTH‐secreting Pancreatic Neuroendocrine Neoplasms: A Case‐Series - Al‐Toubah - Journal of Neuroendocrinology - Wiley Online Library #neuroendocrine #NET onlinelibrary.wiley.com/doi/abs/10.111…

Now online Endotext, the most read and free source of endocrinology worldwide: a completely updated chapter: Gastrointestinal NET and the Carcinoid Syndrome. Including new classifications, diagnostic modalities and treatment options. Read all about it📢! endotext.org/chapter/gastro…

Intruiging potential new option for refractory hypoglycemia in malignant insulinoma: insulin receptor antibody RZ358. Hopefully the first case of many to proof efficacy and improve outcome for these difficult functioning NET cases.
www-nejm-org.eur.idm.oclc.org/doi/10.1056/NE…

📢 Endocrine Oncology is pleased to announce a new special collection evaluating current knowledge on #CarcinoidSyndrome .

⭐ Expertly led by Dr Hans Hofland

Learn more and submit 👉 ow.ly/b2wN50Pnp94

Your PhD is about the evolution of your mindset.

It proceeds through personal research experience, mentorship and development of key skills.

This is why PhD in STEM:

- is NOT about a thesis (very few people will read it)
- is NOT about finish your advisor’s project
- is NOT